Vanda Pharmaceuticals Q4 revenue rises 8% on Fanapt sales

Vanda Pharmaceuticals

11/02/2026 21:10

Overview

Biopharmaceutical firm's Q4 revenue rose 8% yr/yr, driven by Fanapt sales growth

Company reported a significant Q4 net loss due to a one-time tax charge

Outlook

Vanda expects 2026 total revenues of $230 to $260 mln from marketed products

Company anticipates Fanapt 2026 sales of $150 to $170 mln

Vanda preparing NEREUS commercial launch following FDA approval

Result Drivers

FANAPT SALES GROWTH - Fanapt sales increased 24% in 2025, driven by a 28% rise in total prescriptions and 149% surge in new-to-brand prescriptions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$2.39
Q4 Net Income
-$141.19 mln
Q4 Basic EPS
-$2.39
Q4 Operating Expenses
$97.57 mln
Q4 Operating Income
-$40.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $12.50, about 68.5% above its February 10 closing price of $7.42

Press Release: ID:nPn5rWbSXa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)